Overview

A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ipragliflozin